NCT05509790进行中（未招募）1 期
A Phase 1 Study of LY3484356 in Chinese Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 17
- 试验地点
- 4
- 主要终点
- Pharmacokinetics (PK): Plasma Concentration of LY3484356
研究概览
简要总结
This is a study of LY3484356 in Chinese participants with advanced breast cancer. Participants must have breast cancer that is estrogen receptor positive (ER+), HER2 negative (HER2-). The purpose of this study is to measure how much LY3484356 gets into the bloodstream and how long it takes the body to remove it. The safety and effectiveness of LY3484356 will also be studied. Participation could last up to 28 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Native Chinese participants must be of an acceptable age to provide informed consent
- •Have locally advanced (not amenable to curative treatment by surgery) or metastatic disease and be an appropriate candidate for experimental therapy in the judgment of the investigator, after available standard therapies have ceased to provide clinical benefit
- •Have a diagnosis of ER+, HER2- breast cancer
- •Female participants have postmenopausal status due either surgical/natural menopause or ovarian suppression
- •If postmenopausal status is due to ovarian suppression, participants must have a negative serum pregnancy test and agree to use highly effective, medically approved precautions to prevent pregnancy
- •Have a performance status less than or equal to (≤)1 on the Eastern Cooperative Oncology Group (ECOG) scale
- •Have adequate organ function
- •Must be able to swallow capsules/tablets
排除标准
- •Have symptomatic central nervous system (CNS) metastasis and/or carcinomatous meningitis
- •Have a serious concomitant systemic disorder
- •Human immunodeficiency virus (HIV) positive patients are excluded unless they are well controlled on highly active antiretroviral therapy with no evidence of autoimmune deficiency syndrome-defining opportunistic infections within the last 2 years, and cluster of differentiation 4 (CD4) count greater than (>)350 cells/microliter (μL)
- •Active hepatitis B or C virus infection
- •Severe renal impairment, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in clinically significant diarrhea
- •Have visceral crisis
- •Have a serious cardiac condition
- •Have an acute leukemia or other relevant cancers
- •Females who are pregnant or lactating
- •Known allergic reaction against any of the components of the study drug
研究组 & 干预措施
LY3484356 Dose Level 1
Experimental
Administered orally.
干预措施: LY3484356 (Drug)
LY3484356 Dose Level 2
Experimental
Administered orally.
干预措施: LY3484356 (Drug)
结局指标
主要结局
Pharmacokinetics (PK): Plasma Concentration of LY3484356
时间窗: Time Frame: Cycle 1, Day 1 through Day 3 and Day 17 through Day 18; Cycle 2 Day 1 (Cycle 1 = 30 days, Cycle 2 = 28 days)
PK: Plasma Concentration of LY3484356
次要结局
- 2. Percentage of Participants Who Achieve a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR): Overall Response Rate (ORR)(Randomization to Disease Progression or Death from Any Cause (Estimated up to 28 months))
- Disease Control Rate (DCR): Percentage of Participants With a BOR of Complete Response (CR), Partial Response (PR) or Stable Disease (SD)(Randomization to Disease Progression or Death from Any Cause (Estimated up to 28 months))
- Progression-Free Survival (PFS)(Randomization to Disease Progression or Death from Any Cause (Estimated up to 28 months))
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTSBreast NeoplasmsNCT04852419Zentera Therapeutics HK Limited12
已完成
3 期
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyEsophagogastric Junction CarcinomaEsophageal CarcinomaNCT03933449Merck Sharp & Dohme LLC123
终止
1 期
Clinical Study of KN052 in Chinese Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT05309512Jiangsu Alphamab Biopharmaceuticals Co., Ltd15
Unknown
1 期
A Study of LXI-15029 in Patients With Advanced Malignant Solid TumorsAdvanced Breast CancerNCT03125746Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.72
已完成
1 期
To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid MalignanciesSolid MalignanciesNCT05866354Zai Lab (Shanghai) Co., Ltd.19